HomeCompareKDMN vs SPHD

KDMN vs SPHD: Dividend Comparison 2026

KDMN yields 21.05% · SPHD yields 4.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KDMN wins by $51.3K in total portfolio value
10 years
KDMN
KDMN
● Live price
21.05%
Share price
$9.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$77.9K
Annual income
$7,528.57
Full KDMN calculator →
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →

Portfolio growth — KDMN vs SPHD

📍 KDMN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKDMNSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KDMN + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KDMN pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KDMN
Annual income on $10K today (after 15% tax)
$1,789.47/yr
After 10yr DRIP, annual income (after tax)
$6,399.28/yr
SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
At 15% tax rate, KDMN beats the other by $5,913.66/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KDMN + SPHD for your $10,000?

KDMN: 50%SPHD: 50%
100% SPHD50/50100% KDMN
Portfolio after 10yr
$52.2K
Annual income
$4,049.95/yr
Blended yield
7.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KDMN right now

KDMN
Analyst Ratings
8
Buy
2
Hold
1
Sell
Consensus: Buy
SPHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KDMN buys
0
SPHD buys
0
No recent congressional trades found for KDMN or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKDMNSPHD
Forward yield21.05%4.33%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$77.9K$26.5K
Annual income after 10y$7,528.57$571.32
Total dividends collected$45.4K$5.1K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: KDMN vs SPHD ($10,000, DRIP)

YearKDMN PortfolioKDMN Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$12,805$2,105.26$11,133$432.85+$1.7KKDMN
2$16,221$2,519.48$12,363$450.36+$3.9KKDMN
3$20,339$2,982.77$13,695$467.39+$6.6KKDMN
4$25,258$3,495.36$15,138$483.90+$10.1KKDMN
5$31,083$4,056.75$16,697$499.88+$14.4KKDMN
6$37,925$4,665.68$18,382$515.31+$19.5KKDMN
7$45,900$5,320.19$20,198$530.17+$25.7KKDMN
8$55,130$6,017.70$22,157$544.46+$33.0KKDMN
9$65,745$6,755.04$24,266$558.18+$41.5KKDMN
10$77,875$7,528.57$26,536$571.32+$51.3KKDMN

KDMN vs SPHD: Complete Analysis 2026

KDMNStock

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleoside Inhibitor to treat hepatitis; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. The company was founded in 2010 and is headquartered in New York, New York.

Full KDMN Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this KDMN vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KDMN vs SCHDKDMN vs JEPIKDMN vs OKDMN vs KOKDMN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.